Recruiting
A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
ClinicalTrials.gov IDNCT07281001
PhaseNA
Enrollment60
SponsorBlokhin's Russian Cancer Research Center
Age18 Years
SexALL
Conditions studied
HER2-positive Breast Cancer, Trastuzumab Deruxtecan
About this study
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Interventions
- Drug: T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. — T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. Intravenous infusion
Primary outcomes
- PFS (6 weeks)
Eligibility information
Inclusion Criteria:
1. Patients aged over 18 years old.
2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
3. Patients has received Trastuzumab Deruxtecan
4. Available medical history.
Exclusion Criteria:
1. Incomplete medical history.
2. Pregnancy or breast-breeding
Study locations
- Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation, Moscow, 115522 Russia
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-03.